Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Active Surveillance for Single Ground-glass Opacities

Recruiting

Conditions: Lung Ground-glass Opacities
Watchful Waiting

Interventions: Procedure: Active surveillance

First Posted Date: 2024-05-01

Last Posted Date: 2024-07-09

Lead Sponsor: Fudan University

Target Recruit Count: 290

Registration Number: NCT06394037

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Combination Product: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells

First Posted Date: 2024-05-01

Last Posted Date: 2024-05-01

Lead Sponsor: Fudan University

Target Recruit Count: 12

Registration Number: NCT06394622

Locations: 🇨🇳
Fudan University, Shanghai, Shanghai, China

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Phase 2

Not yet recruiting

Conditions: RECTAL NEOPLASMS
Rectal Cancer

Interventions: Radiation: Radiotherapy
Drug: Tislelizumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT06390982

clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases

Recruiting

Conditions: Breast Cancer
Bone Metastases

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 500

Registration Number: NCT06392217

Locations: 🇨🇳
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2

Recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

Interventions: Drug: LM-108
Drug: Toripalimab
Drug: Nab paclitaxel
Drug: Eribulin

First Posted Date: 2024-04-29

Last Posted Date: 2024-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06387628

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Phase 1

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: JS001
Drug: JS004
Drug: JS007
Drug: JS015
Drug: Irinotecan Liposome Injection
Drug: Nab paclitaxel
Drug: 5-Fluorouracil (5-FU)
Drug: Gemcitabine
Drug: Leucovorin (LV)

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Fudan University

Target Recruit Count: 117

Registration Number: NCT06370754

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Recruiting

Conditions: Non-small Cell Lung Cancer
Histology Transformation
Neuroendocrine Carcinoma

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-23

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT06369181

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Transcriptomic Analysis of Incisional Hernia Based on High-throughput Sequencing Technology

Completed

Conditions: Incisional Hernia
Extracellular Matrix Alteration

Interventions: Diagnostic Test: Transcriptomic analysis

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Fudan University

Target Recruit Count: 36

Registration Number: NCT06366581

Locations: 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: PD-1
Drug: Nab-paclitaxel
Drug: Gemcitabine
Radiation: PULSAR

First Posted Date: 2024-04-11

Last Posted Date: 2024-06-25

Lead Sponsor: Fudan University

Target Recruit Count: 81

Registration Number: NCT06359275

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanhai, China

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Sacituzumab Govitecan

First Posted Date: 2024-04-10

Last Posted Date: 2024-04-10

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT06356519

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy